NMRA NEUMORA THERAPEUTICS INC

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY.

A live webcast of the fireside chat will be available on the events and presentations section of the Company’s website at . A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Neumora

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

Neumora Contact:

Helen Rubinstein

617-402-5700



EN
04/02/2026

Underlying

NMRANEUMORA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUMORA THERAPEUTICS INC

 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Bi...

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY. A live webcast of the fireside ch...

February 4, 2026 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated...

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operation...

January 5, 2026 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b...

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect  NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:0...

January 5, 2026 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and ...

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1 studies with two potentially best-in-class positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, with comprehensive franchise update expected by mid-2026 On-track to report data from Phase 1b study of NMRA-511 in Alzheimer’s disease agitation around...

November 6, 2025 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics to Participate in Upcoming Conferences in Novembe...

Neumora Therapeutics to Participate in Upcoming Conferences in November WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in two investor conferences in November. Guggenheim 2nd Annual Healthcare Innovation Conference: Members of management will participate in a fireside chat on Monday, November 10, 2025...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch